

AMAG PHARMACEUTICALS INC.

Form 8-K

August 03, 2017

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 3, 2017

AMAG PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of incorporation)  
001-10865      04-2742593  
(Commission File (IRS Employer Identification  
Number)      No.)  
1100 Winter St.  
Waltham, Massachusetts      02451  
(Address of principal executive      (Zip Code)  
offices)

(617) 498-3300  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 2.02. Results of Operations and Financial Condition.

The following information and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) except as expressly set forth by specific reference in such filing.

On August 3, 2017, AMAG Pharmaceuticals, Inc. (“AMAG”) issued a press release entitled “AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update” regarding its operating results for the quarter and six months ended June 30, 2017 and its intention to hold a conference call to discuss AMAG’s financial and operating results and recent business highlights. A copy of AMAG’s press release is furnished herewith as Exhibit 99.1 and a copy of the presentation slides to be used during the conference call is furnished herewith as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

AMAG hereby furnishes the following exhibits:

Exhibit Number	Description
99.1	Press release entitled “AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update” issued by AMAG Pharmaceuticals, Inc. on August 3, 2017.
99.2	Copy of AMAG Pharmaceuticals, Inc.’s presentation slides dated August 3, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMAG PHARMACEUTICALS, INC.

By: /s/ Joseph D. Vittiglio

Joseph D. Vittiglio

General Counsel, Senior Vice President of Legal Affairs, Technical Operations and Quality and Secretary

Date: August 3, 2017

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release entitled “AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update” issued by AMAG Pharmaceuticals, Inc. on August 3, 2017.
99.2	Copy of AMAG Pharmaceuticals, Inc.’s presentation slides dated August 3, 2017.